Download PDF
TumorDiagnostik & Therapie 2017; 38(10): 629-633
DOI: 10.1055/s-0043-120691
Schwerpunkt Geriatrische Onkologie / onkologische Pflege
© Georg Thieme Verlag KG Stuttgart · New York

Hämatologische Neoplasien beim älteren Menschen

Valentin Goede
Further Information

Publication History

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

Hämatologische Tumoren betreffen vor allem ältere Patienten. Neben ihrer Tumorerkrankung leiden diese häufig an Begleiterkrankungen, die mit Polypharmazie und funktionellen Einschränkungen einhergehen. Dabei schwankt die Prävalenz geriatrischer Syndrome in Abhängigkeit von der jeweiligen hämatologischen Neoplasie und der klinischen Situation.
 

  • Literatur

  • 1 Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum für Krebsregisterdaten, Robert Koch-Institut. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html
    PubMedGoogle Scholar
  • 2 Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res 2014; 38: 275-283
    CrossrefPubMedGoogle Scholar
  • 3 Decoster L, Van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol 2015; 26: 288-300
    CrossrefPubMedGoogle Scholar
  • 4 Wildiers H, Heeren P, Puts M. et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014; 32: 2595-2603
    CrossrefPubMedGoogle Scholar
  • 5 Hurria A, Togawa K, Mohile SG. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457-3465
    CrossrefPubMedGoogle Scholar
  • 6 Extermann M, Boler I, Reich RR. et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377-3386
    CrossrefPubMedGoogle Scholar
  • 7 Magnuson A, Allore H, Cohen HJ. et al. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. J Geriatr Oncol 2016; 7: 242-248
    CrossrefPubMedGoogle Scholar
  • 8 Goede V. New Developments in Geriatric Oncology. Dtsch Med Wochenschr 2017; 142: 163-168
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Krug U, Röllig C, Koschmieder A. et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008
    CrossrefPubMedGoogle Scholar
  • 10 Klepin HD. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clin Geriatr Med 2016; 32: 155-173
    PubMedGoogle Scholar
  • 11 Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep 2016; 6: 1-7
    PubMedGoogle Scholar
  • 12 Gugliotta G, Castagnetti F, Apolinari M. et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 2014; 74: 627-643
    CrossrefPubMedGoogle Scholar
  • 13 Russo D, Malagola M, Skert C. et al. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J 2015; 5: e347
    CrossrefPubMedGoogle Scholar
  • 14 Eichhorst B, Robak T, Montserrat E. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v78-v84
    CrossrefPubMedGoogle Scholar
  • 15 Strati P, Parikh SA, Chaffee KG. et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 2017; 178: 394-402
    CrossrefPubMedGoogle Scholar
  • 16 Stauder R, Eichhorst B, Hamaker ME. et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 2017; 28: 218-227
    PubMedGoogle Scholar
  • 17 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
    CrossrefPubMedGoogle Scholar
  • 18 Tucci A, Martelli M, Rigacci L. et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 2015; 56: 921-926
    CrossrefPubMedGoogle Scholar
  • 19 Böll B, Goergen H, Behringer K. et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189-2192
    CrossrefPubMedGoogle Scholar
  • 20 Gopal AK, Bartlett NL, Forero-Torres A. et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma 2014; 55: 2328-2334
    CrossrefPubMedGoogle Scholar
  • 21 Palumbo A, Bringhen S, Mateos MV. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125: 2068-2074
    CrossrefPubMedGoogle Scholar